BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment

Stock Information for BioAdaptives, In

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioAdaptives, In

UFC Hall of Famer Michael Bisping Backs Xycota Biosciences' Low-Dose Psilocybin Research on PTSD and Concussion
BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research
BioAdaptives Highlights Michael Bisping's MyndMed(TM) Routine in UFC 331 Pre-Show Instagram Video
BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress
UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem(TM)
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara(TM) "Supply and Direction" Platform

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.